How real-time PK/PD monitoring could give the chasing pack an advantage in the GLP-1 market

With Novo Nordisk and Eli Lilly far and away the leaders in the nascent yet exploding obesity commercial market, one option for follow-on competitors to differentiate could be a precision medicine approach that provides either better tolerability, better efficacy, or ideally, both.

Full article here